有投资者在互动平台向爱朋医疗提问："会议倒计时︱第五届脑科学前沿与产业大会暨2025深圳脑机接 口博览会（12月28-30日，深圳）贵公司去参加？" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，爱朋医疗回应称："您好，公司计划参加上述博览会，以加强与行业的交流合作。感谢 您对公司的关注。" ...

Investment Rating - The industry investment rating for the pharmaceutical and biotechnology sector is "Hold" [2]. Core Insights - The report highlights significant breakthroughs in the domestic brain-computer interface (BCI) technology, indicating an acceleration in industry development and international recognition [5]. - The report emphasizes the transition of invasive brain-computer interfaces from laboratory settings to market approval processes, suggesting a rapid expansion of application scenarios [6]. Summary by Relevant Sections Industry Overview - The report discusses the recent advancements in invasive brain-computer interface technology, including the first domestic medical device entering the FDA's breakthrough therapy pathway, which enhances the international recognition of China's BCI technology [5]. - It mentions successful clinical trials using high-throughput wireless invasive BCI systems, enabling patients with high-level paralysis to control smart wheelchairs and robotic dogs through brain signals, achieving a 15%-20% improvement in brain control performance [5]. Investment Recommendations - The report suggests focusing on companies such as Innovation Medical, Aipeng Medical, and Sanbo Brain Science, as they are positioned to benefit from the advancements in the BCI sector [6].

Core Viewpoint - The company Aipeng Medical (300753) is focusing on the development of a multimodal ADHD behavior training system that connects data between in-hospital behavior training centers and at-home training scenarios, utilizing scientific EEG monitoring and multimodal intervention training to help children improve hyperactivity and attention deficit behaviors, thereby enhancing concentration [1] Group 1 - The company has developed a multimodal ADHD behavior training system that integrates data from both hospital and home environments [1] - The system employs scientific EEG monitoring and multimodal intervention training methods to assist children in improving hyperactivity and attention deficit behaviors [1] - The company possesses advanced technology in anesthesia depth monitoring, being one of the few in China to master anesthesia depth index monitoring [1] Group 2 - Aipeng Medical has launched a stubborn insomnia anesthesia treatment system designed to meet clinical needs for treating persistent insomnia, combining hardware and software solutions [1] - The system addresses the digital interaction needs between doctors and patients both in and out of the hospital, providing strong support for clinical treatment [1] - The company plans to advance clinical innovative applications in perioperative brain state monitoring, ADHD, sleep disorders, and epilepsy treatment [1]

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing above the annual line, indicating a slight increase of 0.17% and a total trading volume of 1.665 trillion yuan [1]. Group 1: Market Performance - As of 14:59 today, the Shanghai Composite Index stands at 3876.97 points, above the annual line [1]. - A total of 153 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1]. Group 2: Notable Stocks - The stocks with the highest deviation rates include: - Yimin Group (益民集团) with a deviation rate of 9.76% and a daily increase of 10.11% [1]. - Wanrun Technology (万润科技) with a deviation rate of 6.64% and a daily increase of 7.57% [1]. - Laiyifen (来伊份) with a deviation rate of 5.56% and a daily increase of 10.01% [1]. - Other stocks with smaller deviation rates that have just crossed the annual line include Suzhou Planning (苏州规划), Tianzhihang (天智航), and China Railway Special Cargo (中铁特货) [1].

Core Viewpoint - The company is actively advancing its layout in the brain-computer interface field, with specific investment decisions based on strategic development, business line, product tier needs, and actual circumstances [1] Group 1: Product Development - The company has developed a multimodal ADHD behavior treatment system that includes two products: UMind (hospital version) and SE (home version), which facilitate data interconnection between hospital behavior training centers and home training scenarios [1] - The company plans to initially promote the product through professional channels, leveraging both hospital markets and external professional institutions such as Fangcun Doctors and educational organizations to build a professional barrier for the product [1] Group 2: Market Strategy - The company aims to utilize its extensive e-commerce operational experience to empower future consumer-level promotion of the product in the e-commerce sector [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Group 1 - The company announced a joint investment with Jiangsu Yingjue Private Equity Fund Management Co., Ltd. and Jiaxing Silin Venture Capital Partnership to establish Aipeng Zhilian Cloud Brain (Jiaxing) Equity Investment Partnership [1] - The company will act as a limited partner, contributing RMB 49.7 million, which represents a 49.7% stake in the investment fund [1] - The fund will primarily focus on equity investments in areas such as brain-computer interfaces, neuroscience, mental system diseases, and other healthcare sectors, with an investment period of 4 years and a total duration of 7 years [1]

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-053 江苏爱朋医疗科技股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、与专业投资机构合作投资概述 为满足战略发展需求，充分借助专业投资机构的力量及资源优势，加快推动产业 布局优化，在不影响公司日常经营和发展、有效控制投资风险的前提下，江苏爱朋医 疗科技股份有限公司（以下简称"公司"或"爱朋医疗"）与江苏英掘私募基金管理 有限公司、嘉兴思麟创业投资合伙企业（有限合伙）共同签署了《爱朋智链云脑（嘉 兴）股权投资合伙企业（有限合伙）合伙协议》（以下简称"合伙协议"），根据合 伙协议约定，公司作为有限合伙人以自有资金人民币4,970万元出资认购投资基金份 额，出资比例为49.7%。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第7号——交易与关联交易》及《公司章程》等相关规定，上述交易不属于关联 交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组，无需提交 公司董事会及股东会审议。 二、投资基金基 ...

Group 1 - The Jiangxi Provincial Government is accelerating the clinical research of brain-computer interface technology in the treatment of neurological and psychiatric diseases, as well as in elderly rehabilitation [1] - The government supports medical institutions in establishing clinical research wards and cohorts for brain-computer interface technology [1] - The establishment of the Jiangxi Brain-Computer Interface Rehabilitation Center and high-quality data sets for the EEG industry in the Ganjiang New Area is also being promoted [1] Group 2 - Aipeng Medical (300753.SZ) confirmed that its perioperative brain state monitoring product, the anesthesia depth monitor, has generated sales revenue in Jiangxi Province, although the revenue impact is relatively small [1]